Clinical trial

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

NCT07416474

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-04-03

PhasePHASE3

Study timeline

Study start (actual)2026-04-03Date precision: day

Registry last updated2026-07-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerunresolved

Interventions

RC148 plus Carboplatin and PaclitaxelDRUG

Tislelizumab plus Carboplatin and PaclitaxelDRUG

Sponsors & collaborators

RemeGen Co., Ltd.lead sponsor

Mapped research locations

GuangzhouGuangdong, China4 NanjingJiangsu, China3 ZhengzhouHenan, China3 ChongqingChongqing Municipality, China3 ShanghaiShanghai Municipality, China2 ShanghaiChina2 HangzhouZhejiang, China2 ChengduSichuan, China2 TianjinTianjin Municipality, China2 ShenyangLiaoning, China2 WuhanChina2 FuzhouFujian, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07416474 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.